Updates are available Erratum dated 2022-01-15
Click to view Erratum: https://doi.org/10.1016/s0140-6736(22)00019-8
-
Authors
Halperin, Scott A
Ye, Lingyun
MacKinnon-Cameron, Donna
Smith, Bruce
Cahn, Pedro E
Ruiz-Palacios, Guillermo M
Ikram, Aamer
Lanas, Fernando
Lourdes Guerrero, M
Muñoz Navarro, Sergio Raúl
Sued, Omar
Lioznov, Dmitry A
Dzutseva, Vitalina
Parveen, Ghazala
Zhu, Fengcai
Leppan, Laura
Langley, Joanne M
Barreto, Luis
Gou, Jinbo
Zhu, Tao
Mao, Helen
Gagnon, Luc
Tran, Steven-Phay
Khan, Sarwat Tahsin
Becerra Aquino, Amalia Guadalupe
Saldaña Montemayor, Edgar Eduardo
Rivera Martínez, Norma Eréndira
Bohórquez López, Víctor Casildo
Simón Campos, J. Abraham
Pineda Cárdenas, Felipe de Jesús
Chen, Wei
Hou, Lihua
Zhang, Zhe
Corral, Gonzalo
López, Eduardo
Teijeiro, Ricardo
Alzogaray, Maria F.
Zaidman, Cesar
Lopardo, Gustavo
Goecke, Bernardo
Feijooó Seoane, Rosa María
Mahmood, Sayed Faisal
Khan, Ejaz Ahmed
Akram, Jayed
Abbas, Salma
Salahuddin, Naseem
Rozhkova, Elena
Zubkova, Tatyana
-
Funding
Funding for this research was provided by:
Beijing Institute of Technology
- License Information
-
More Information
This article is maintained by: Elsevier
Article Title: Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
Journal Title: The Lancet
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(21)02753-7
CrossRef DOI link to the associated document: https://doi.org/10.1016/S0140-6736(21)02834-8
Content Type: article
Copyright: © 2021 Elsevier Ltd. All rights reserved.
